FDA Reform Bill Will Keep Firms Scrambling To Stay Ahead On Safety Issues
Executive Summary
Pharmaceutical companies need to immediately begin assessing whether their drugs are subject to the risk evaluation and mitigation strategies provisions of the FDA Amendments Act, participants were warned during a Food and Drug Law Institute audioconference on the new law, Oct. 4
You may also be interested in...
Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps
Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline
Can Prometheus Light A Fire Under Lotronex? GI Specialty Firm Will Add Reps
Prometheus Laboratories has lofty expectations for Lotronex (alosetron), the irritable bowel syndrome drug it is acquiring from GlaxoSmithKline
Will FDA/CMS Parallel Review Idea Make Headway This Time?
The possibility of simultaneous FDA and CMS evaluations of new health products is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube